[Introduction] On January 19, 2026, Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, led a delegation to Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) for an on-site inspection. The two sides engaged in in-depth discussions on topics including deepening government-enterprise cooperation, accelerating the commercialization of innovation outcomes, and optimizing the business environment.

Going to the Front Lines to Witness the “Jeyou Speed”

On the morning of January 19, Deputy District Governor Xu Lei and his delegation arrived at Jeyou Pharma’s R&D headquarters in Zhangjiang Science City. Accompanied by Jeyou Pharma President Li Zhan and the management team, they gained a detailed understanding of the company’s development history and latest achievements.

Jeyou Pharmaceuticals, the R&D and innovation headquarters spun off from the Jimin Kexin Group, has consistently adhered to a “clinical value-oriented” innovation strategy since its establishment in Pudong in 2018. The company has built a comprehensive drug R&D innovation system spanning the entire lifecycle—from drug discovery and preclinical development to clinical trials and regulatory approval. During the research visit, the company reported recent good news: in January 2026, Jeyou Pharma successfully completed a Series A financing round of nearly 2 billion RMB. Currently, the company has established a “3+1” indication matrix centered on oncology, nephrology, pain, and autoimmune diseases, with over 40 projects in development: one licensed product has been launched and is on the market; one pipeline has submitted a New Drug Application (NDA); four pipelines (covering seven indications) are in Phase II clinical trials or the Proof of Concept (POC) stage; 10 projects are in Phase I clinical trials; and more than 20 preclinical candidate compounds (PCCs) are under development.

Roundtable Discussion: Empowering the “Leader of Success”

During the subsequent roundtable discussion, both parties engaged in an in-depth exchange. Deputy District Governor Xu Lai listened to the company’s presentation on its national strategic layout, the functional positioning of its Pudong operations, and its future development plans.

Xu Lai expressed full recognition of the achievements Jeyou Pharmaceutical has made through its commitment to innovation-driven development, praising the company as a “pioneer among successful enterprises,” and noted that the District Party Committee and District Government attach great importance to the development of the biopharmaceutical industry.

She urged the company to remain confident, deepen its roots in Shanghai, and seize opportunities by fully leveraging business support policies such as the “one-company-one-policy” initiative. She encouraged the company to further expand and strengthen its core business, consolidate the functions of its Shanghai R&D headquarters, and truly anchor its R&D pipeline and core resources in Pudong; At the same time, she encouraged the company to expand diverse innovation partnerships, actively participate in Pudong’s economic development, leverage the government’s comprehensive support for initial public offerings (IPOs) and the advancement of clinical projects, continuously enhance its R&D capabilities and the core competitiveness of its products, accelerate the delivery of innovative medicines to benefit more patients, and contribute to the high-quality development of Pudong’s biopharmaceutical industry.

Company Response: Deepening Roots in Shanghai, Expanding Across the Yangtze River Delta

Li Zhen, President of Jeyou Pharmaceuticals, expressed gratitude on behalf of the company for the recognition and support from the Pudong New Area government. He noted that the affirmation of Jeyou Pharmaceuticals’ past achievements by New Area leaders during this visit has further strengthened the company’s confidence and resolve regarding future development.

Li Yan emphasized that Jeyou Pharmaceuticals will remain steadfast in its strategic focus, resolutely implementing the strategic layout of “Deepening Roots in Shanghai, Expanding Across the Yangtze River Delta.” The company will deeply integrate its innovation blueprint into Pudong’s biopharmaceutical industry ecosystem, actively responding to the expectations of the government and the market with solid R&D achievements and sound operational performance. It is committed to becoming an industry benchmark and establishing itself as a “Pudong Model” for China’s innovative pharmaceutical enterprises.

Discussing the Business Environment: Tailored Policies, Precise Support

During the meeting, both sides engaged in candid discussions regarding the company’s current practical needs. In response to Jeyou Pharma’s specific requests—including “tailored policies” for policy support and guarantees for surrounding infrastructure—Deputy District Governor Xu Lai and accompanying officials from the District Science, Technology, and Economy Commission, the Zhangjiang Science and Technology Construction Office, and the Zhangjiang Group all offered positive responses.

District leaders stated that Pudong will continue to optimize the business environment, provide tailored services for key enterprises and projects, effectively address enterprises’ concerns regarding infrastructure support and talent recruitment, and safeguard the high-quality development of Jeyou Pharmaceuticals.

Conclusion

This visit not only demonstrates Pudong New Area’s strong commitment to the biopharmaceutical industry but also serves as a significant boost to Jeyou Pharma’s future development. Under the combined efforts of “an active government and an efficient market,” Jeyou Pharma will continue to accelerate the global development and commercialization of innovative drugs, contributing the “Jeyou strength” to the rise of China’s biopharmaceutical industry.